257 related articles for article (PubMed ID: 17999990)
21. Clinical relevance of HBV DNA load in patients with chronic hepatitis B infection.
Madan K; Batra Y; Jha JK; Kumar S; Kalra N; Paul SB; Singh R; Duttagupta S; Panda SK; Acharya SK
Trop Gastroenterol; 2008; 29(2):84-90. PubMed ID: 18972767
[TBL] [Abstract][Full Text] [Related]
22. Molecular and serological characterization of hepatitis B virus in deferred Ghanaian blood donors with and without elevated alanine aminotransferase.
Candotti D; Opare-Sem O; Rezvan H; Sarkodie F; Allain JP
J Viral Hepat; 2006 Nov; 13(11):715-24. PubMed ID: 17052270
[TBL] [Abstract][Full Text] [Related]
23. Association of concurrent hepatitis B surface antigen and antibody to hepatitis B surface antigen with hepatocellular carcinoma in chronic hepatitis B virus infection.
Jang JS; Kim HS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Kim DJ; Lee MS; Park CK; Jeong BH; Kim YS; Jang MK
J Med Virol; 2009 Sep; 81(9):1531-8. PubMed ID: 19623669
[TBL] [Abstract][Full Text] [Related]
24. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study.
Liu CJ; Chen BF; Chen PJ; Lai MY; Huang WL; Kao JH; Chen DS
J Infect Dis; 2006 Sep; 194(5):594-9. PubMed ID: 16897657
[TBL] [Abstract][Full Text] [Related]
25. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection.
Hung IF; Poon RT; Lai CL; Fung J; Fan ST; Yuen MF
Am J Gastroenterol; 2008 Jul; 103(7):1663-73. PubMed ID: 18616655
[TBL] [Abstract][Full Text] [Related]
26. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers.
Liu CJ; Chen BF; Chen PJ; Lai MY; Huang WL; Kao JH; Chen DS
J Infect Dis; 2006 May; 193(9):1258-65. PubMed ID: 16586363
[TBL] [Abstract][Full Text] [Related]
27. The impact of hepatitis B viral load on recurrence after complete necrosis in patients with hepatocellular carcinoma who receive transarterial chemolipiodolization: implications for viral suppression to reduce the risk of cancer recurrence.
Jang JW; Choi JY; Bae SH; Yoon SK; Woo HY; Chang UI; Kim CW; Nam SW; Cho SH; Yang JM; Lee CD
Cancer; 2007 Oct; 110(8):1760-7. PubMed ID: 17724708
[TBL] [Abstract][Full Text] [Related]
28. Aboriginal Taiwanese hepatitis B carriers have more favorable viral factors than Han Chinese carriers.
Nien HC; Sheu JC; Kao JH; Chou HC; Su CW; Chen CH
J Med Virol; 2011 Aug; 83(8):1326-31. PubMed ID: 21678436
[TBL] [Abstract][Full Text] [Related]
29. Quantitative HBV DNA and AST are strong predictors for survival after HCC detection in chronic HBV patients.
Witjes CD; IJzermans JN; van der Eijk AA; Hansen BE; Verhoef C; de Man RA
Neth J Med; 2011; 69(11):508-13. PubMed ID: 22279629
[TBL] [Abstract][Full Text] [Related]
30. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.
Lee MH; Yang HI; Liu J; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; You SL; Wang LY; Chen CJ;
Hepatology; 2013 Aug; 58(2):546-54. PubMed ID: 23504622
[TBL] [Abstract][Full Text] [Related]
31. High prevalence of hepatitis B virus infection and inferior vena cava obstruction among patients with liver cirrhosis or hepatocellular carcinoma in Nepal.
Shrestha SM; Shrestha S; Shrestha A; Tsuda F; Endo K; Takahashi M; Okamoto H
J Gastroenterol Hepatol; 2007 Nov; 22(11):1921-8. PubMed ID: 17914971
[TBL] [Abstract][Full Text] [Related]
32. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Ohata K; Hamasaki K; Toriyama K; Ishikawa H; Nakao K; Eguchi K
J Gastroenterol Hepatol; 2004 Jun; 19(6):670-5. PubMed ID: 15151623
[TBL] [Abstract][Full Text] [Related]
33. [Investigation of the relationship between serum nitric oxide levels, HBV-DNA and ALT levels in chronic hepatitis B patients].
Sener AG; Kirdar S; Serter M; Afşar I; Demir EM; Ceylan C; Aydin N
Mikrobiyol Bul; 2009 Jan; 43(1):83-9. PubMed ID: 19334384
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis B virus DNA in patients with hepatitis B-related liver cirrhosis with or without hepatocellular carcinomas: a matched case-control study.
Xu J; Lin Y; Wang YP; Chen YX; Shi B; Lu J; Xie WF
J Dig Dis; 2009 May; 10(2):138-44. PubMed ID: 19426397
[TBL] [Abstract][Full Text] [Related]
35. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.
Iloeje UH; Yang HI; Su J; Jen CL; You SL; Chen CJ;
Gastroenterology; 2006 Mar; 130(3):678-86. PubMed ID: 16530509
[TBL] [Abstract][Full Text] [Related]
36. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
[TBL] [Abstract][Full Text] [Related]
37. Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies.
Tung HD; Wang JH; Tseng PL; Hung CH; Kee KM; Chen CH; Chang KC; Lee CM; Changchien CS; Chen YD; Lu SN
Am J Gastroenterol; 2010 Mar; 105(3):624-31. PubMed ID: 20051944
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis B virus DNA in liver tissue and risk for hepatocarcinogenesis in patients with hepatitis C virus-related chronic liver disease. A prospective study.
Obika M; Shinji T; Fujioka S; Terada R; Ryuko H; Lwin AA; Shiraha H; Koide N
Intervirology; 2008; 51(1):59-68. PubMed ID: 18349544
[TBL] [Abstract][Full Text] [Related]
39. [The significance of anti-HBc and occult hepatitis B virus infection in the occurrence of hepatocellular carcinoma in patients with HBsAg and anti-HCV negative alcoholic cirrhosis].
Kim MJ; Kwon OS; Chung NS; Lee SY; Jung HS; Park DK; Ku YS; Kim YK; Kim YS; Kim JH
Korean J Hepatol; 2008 Mar; 14(1):67-76. PubMed ID: 18367859
[TBL] [Abstract][Full Text] [Related]
40. Serum aminotransferase level and the risk of hepatocellular carcinoma: a population-based cohort study in Japan.
Ishiguro S; Inoue M; Tanaka Y; Mizokami M; Iwasaki M; Tsugane S;
Eur J Cancer Prev; 2009 Feb; 18(1):26-32. PubMed ID: 19077561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
